Fasudil fOr redUcing elopemeNt and Spatial Disorientation

Woolsey Pharmaceuticals24 enrolled

Overview

Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating. The aim of the study is to assess the effectiveness of oral fasudil in reducing wandering behaviors of elopement and/or getting lost in subjects with dementia. In addition, effects on wandering behaviors of excess movement and pacing, cognition, memory, neuropsychiatric symptomatology, caregiver/nursing staff burden, and the safety and tolerability of fasudil treatment will be assessed.

The study population will consist of subjects with dementia and wandering behaviors of elopement and/or getting lost. While it is anticipated that most participants will be residing at home (with caregiver support), subjects may live in another setting such as a group home, an assisted living unit, or in a long-term care facility, provided that a caregiver, formal or informal, has sufficient contact with the subject to permit accurate completion of the necessary assessments. Enrolled subjects will enter the Open-Label Phase and receive treatment with fasudil 90 mg/day (30 mg three times daily \[tid\]) for 6 weeks in Open-Label Period 1. Responders (i.e., subjects who improve 2 points or more on the GIW) will proceed to the Double-Blind Phase. Subjects in whom fasudil is well-tolerated (i.e. subjects with ≤ 2 drug-related AEs of mild intensity, no drug-related AEs of greater than mild intensity, and creatinine level of \< 1.5 mg/dL at all times during the period) and who do not respond will enter Open-Label Period 2, and be dosed with fasudil 180 mg/day (60 mg tid) for 6 weeks. Responders will proceed to the Double-Blind Phase and non-responders will move to the final post-treatment visit. In the Double-Blind Phase, subjects will receive treatment with either placebo or the dose they responded to in the Open-Label Phase (90 mg/day or 180 mg/day) for 6 weeks (Double-Blind Period 1), following which treatment assignment will be crossed over for 6 weeks (Double-Blind Period 2). A final post-treatment visit will occur 14 days after the last dose of study drug. Visits may be performed by qualified healthcare professionals at home or other care setting, or at a doctor's office/clinic. Interviews may be performed by telephone and/or telemedicine as appropriate. Study Endpoints: Primary: • The Global Impression of Wandering (GIW) Secondary: * Weekly Wandering Report - Community Version (WWR-C) * The Revised Algase Wandering Scale - Community Version (RAWS-CV) * The Mini Mental State Examination (MMSE) * The Neuropsychiatric Inventory-Questionnaire (NPI-Q) * The Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C) * The Center for Neurological Study-Lability Scale (CNS-LS) * The Zarit Burden Interview (ZBI) * Safety * Tolerability

Conditions

Dementia

Interventions

Oral Fasudil 90 mg/dayDRUG

Oral tablet

Oral Fasudil 180 mg/dayDRUG

Oral tablet

Oral PlaceboDRUG

Oral tablet

Eligibility

Sex: ALLMin age: 50 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 50 to 90 years of age (inclusive). 2. Diagnosis of dementia of any etiology. 3. MMSE 9-24 (inclusive). 4. Presence of one or both of the following wandering behaviors that in the opinion of the investigator, in consultation with caregiver, is at least of moderate severity (defined as clearly a wanderer, and this causes some distress or difficulty for both the subject and caregiver): 1. Elopes or attempts to elope AND/OR 2. Gets lost or is unable to locate a specific place. 5. Independently ambulatory with or without assistive devices (such as canes or walkers). Subjects must not require assistance to transfer out of bed or a chair. 6. Subject has a caregiver who has more than 10 hours/week of contact with the subject, is fluent and literate in English and is willing to accept responsibility for supervising the treatment (e.g., administering study drug) and assessing the condition of the subject throughout the study in accordance with all protocol requirements. 7. Consent obtained from the participant/legally authorized representative (LAR) in accordance with local regulations. Exclusion Criteria: 1. Expected change in medication that could interfere with the study or free movement of the subject. 2. Serum creatinine ≥ 1.5 mg/dL. 3. ALT and/or alkaline aminotransferase (AST) ≥ 2 X and/or alkaline phosphatase (ALP) ≥ 1.5 upper limit of normal. 4. Blood pressure \< 90/60. 5. On more than one of the following drug classes: long-acting nitrates, beta-blockers, or calcium channel blockers. 6. Any severe comorbidity that in the opinion of the Investigator would disallow safe participation in the trial. 7. Women of child-bearing potential; females must be postmenopausal or surgically sterilized. 8. Suicidal ideation per the Columbia-Suicide Severity Rating Scale (C-SSRS) that in the opinion of the PI would pose a safety risk or interfere with the appropriate interpretation of study data. 9. Planned change in the current living setting during the study. 10. History within the last year of either two or more falls leading to clinically significant injuries or one or more fall leading to hospitalization, and/or evidence of orthostatic hypotension. 11. Participation in another investigational drug study within 30 days before start of Open-Label period. 12. Subjects who, in the opinion of the investigator, are not suitable for the study.

Locations (11)

New England Institute for Clinical Research

Stamford, Connecticut, United States

Accel Research Sites

Lakeland, Florida, United States

Lakes Research, LLC.

Miami Lakes, Florida, United States

Outcomes

Primary Outcomes

Change in Global Impression of Wandering (GIW) after oral Fasudil vs placebo in the Double-Blind Phase

The GIW is a variant of the 7-point Clinical Global Impression-Severity (CGI-S) scale and is used in FOUND specifically to obtain the investigator's overall assessment of severity of the subject's wandering behavior.

Time frame: Week 6 and Week 12 of the Double-Blind period

Secondary Outcomes

Change in Weekly Wandering Report - Community Version (WWR-C)

The WWR-C is composed of targeted questions related to excess walking, spontaneous pacing, elopement, and wayfinding; it is designed to be assessed on a weekly basis by caregivers about subjects for whom they care. The WWR-C asks the caregiver to rate the subject's behavior for the previous week.

Time frame: Weekly during the 12 weeks of the Double-Blind period

Change in the Revised Algase Wandering Scale - Community Version (RAWS-CV)

The RAWS-CV is a 40-item tool with 6 subscales to assess wandering behaviors (eloping behaviors, negative outcomes, mealtime impulsivity, persistent walking, repetitive walking, and spatial disorientation), and a total score scale.

Time frame: Week 6 and Week 12 of the Double-Blind period

Change in Mini Mental State Examination (MMSE)

The MMSE is a 30-point questionnaire that is used to measure cognitive impairment.

Time frame: Week 6 and Week 12 of the Double-Blind period

Change in Neuropsychiatric Inventory-Questionnaire (NPI-Q)

The NPI-Q provides an assessment of dementia-related emotional behavioral symptomatology in routine clinical practice settings. Caregiver distress is also assessed. The NPI-Q asks the assessor to rate the previous 30 days. At the Final Visit, the assessor will rate the NPI-Q for the 2-week period following the final dose. The scale is completed by the caregiver without input from the subject. All reasonable efforts should be made to ensure each NPI-Q for an individual subject is completed by the same caregiver to minimize inter-rater variability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.